Syneron Bio Raises $150M for Macrocyclic Peptide Drug Development
Beijing-based Syneron Bio raised $150M in Series B funding with AstraZeneca among investors to develop macrocyclic peptide drugs. The FDA also proposed a new expedited IND pathway.
#Series b
1 story